Cancers Associated with BRCA1 and BRCA2 Mutations

BRCA1 and BRCA2 mutations are most strongly linked to breast and ovarian cancer, but the list of associated cancers extends well beyond those two. Prostate cancer, pancreatic cancer, melanoma, and possibly certain gastrointestinal cancers also appear at elevated rates in carriers. The risks differ substantially depending on which gene is mutated, and the biology behind these mutations has reshaped how several of these cancers are treated.

Breast Cancer in Women

Breast cancer is the cancer most commonly associated with BRCA mutations, and the lifetime risk numbers are striking. In one large study, female carriers faced a lifetime breast cancer risk of roughly 82%, with the risk appearing to climb in more recent generations: women born after 1940 who carried a mutation had a 67% chance of developing breast cancer by age 50, compared with 24% for carriers born before 1940.¹ An earlier analysis of BRCA1 carriers specifically estimated the cumulative risk at about 87% by age 70, factoring in contralateral cancers that develop years after a first diagnosis.²

These figures are averages across study populations and can vary based on the specific mutation, family history, and other genetic and environmental factors. But the overall picture is clear: a woman with a pathogenic BRCA1 or BRCA2 variant faces a breast cancer risk many times higher than the general population, where the lifetime risk sits around 12 to 13 percent.

The tumors that arise in BRCA carriers also tend to look different under a microscope. Breast cancers in BRCA1 carriers are more often high-grade, with a distinctive pattern of rapid cell division, and medullary or atypical medullary carcinoma shows up far more frequently in BRCA1 carriers than in sporadic cases. BRCA2-linked breast cancers are also higher grade than average, but through a somewhat different histological profile: they show less of the organized tubule structures seen in lower-grade tumors, though they do not share the same elevated mitotic count seen in BRCA1 tumors.³ Clinically, BRCA1 breast cancers are frequently triple-negative, meaning they lack the hormone receptors and HER2 overexpression that many standard therapies target, which historically made them harder to treat before newer options became available.

Ovarian Cancer and the Fallopian Tube

Ovarian cancer is the second hallmark cancer of BRCA mutations, and BRCA carriers face a 30- to 40-fold increased risk of high-grade serous carcinoma, the most common and aggressive subtype.⁴ High-grade serous carcinoma is the predominant type seen in hereditary breast and ovarian cancer syndrome, and BRCA1 and BRCA2 mutations account for most of the known genetic causes of that syndrome.⁵

One of the more surprising findings in recent decades is that many of these “ovarian” cancers do not actually start in the ovary. Careful examination of tissue from BRCA carriers who underwent preventive surgery found that early malignancies were concentrated in the fimbriae, the finger-like projections at the end of the fallopian tube closest to the ovary. In one series, all seven early cancers detected originated in the fimbrial or ampullary region of the tube, and several required meticulous sectioning to find.⁶ This discovery shifted how pathologists examine surgical specimens and influenced the design of risk-reduction surgeries, which now emphasize complete removal of the fallopian tubes alongside the ovaries.

Cancers in Men

BRCA mutations are often framed as a women’s health issue, but men who carry these variants face their own set of elevated risks. Male breast cancer is rare in the general population, but BRCA2 carriers have a meaningfully higher chance of developing it. The cumulative risk for male BRCA2 carriers reaches roughly 7% by age 70, compared with about 1% for male BRCA1 carriers.⁷ In high-risk families, BRCA2 variants are estimated to account for 60 to 70 percent of male breast cancer cases, and these tumors tend to be higher grade with a poorer prognosis than male breast cancers not driven by BRCA2.⁸ A clinical series found that all male breast cancer cases in their cohort occurred in BRCA2 carriers, and the majority were high-grade and hormone receptor positive with lymph node involvement.⁹

Prostate cancer is the other major concern for male carriers. A meta-analysis found that the risk of aggressive prostate cancer was roughly doubled for BRCA1 carriers and about six times higher for BRCA2 carriers compared to non-carriers.¹⁰ BRCA2-associated prostate cancers are particularly worrisome because they tend to present at a more advanced stage and carry a shorter survival time.¹¹ Some guidelines now recommend that male BRCA2 carriers begin prostate cancer screening earlier than the general population.

Pancreatic Cancer and Other Sites

Pancreatic cancer occurs at a higher-than-expected rate in both BRCA1 and BRCA2 carriers. A prospective study following over 5,000 women with BRCA mutations found about two and a half times as many pancreatic cancers as expected, with the elevated risk reaching statistical significance for the cohort overall.¹² A larger observational study confirmed the association and uncovered an interesting pattern: the increased risk was especially pronounced in male BRCA1 carriers and female BRCA2 carriers, with a statistically significant interaction between sex and gene.¹³ Having a first-degree relative with pancreatic cancer on top of carrying a BRCA mutation further compounds the risk dramatically.¹⁴

Melanoma has been linked to BRCA2 mutations in several studies, though the evidence is less consistent. Some large family-based studies found an elevated melanoma risk in BRCA2 carriers, while others did not, and only one study reported a statistically significant increase.¹⁵ There have also been possible associations with cancers of the esophagus and stomach, but these findings are based on smaller numbers and need confirmation from larger studies.¹⁶ The evidence gets thinner as you move beyond the core cancers. Most clinicians focus surveillance and prevention on breast, ovarian, prostate, and pancreatic cancers, where the data are strongest.

Why BRCA Mutations Lead to So Many Cancers

BRCA1 and BRCA2 are both involved in repairing a particularly dangerous type of DNA damage: double-strand breaks, where both strands of the DNA helix are severed. The repair pathway they participate in copies intact DNA from a sister chromosome to patch the break accurately. When either BRCA gene is knocked out, cells lose access to this high-fidelity repair method and fall back on sloppier alternatives that introduce errors. Over time, those errors accumulate and can transform a normal cell into a cancerous one.¹⁷

This same vulnerability, paradoxically, creates a therapeutic opportunity. Cells that cannot repair DNA properly are more sensitive to treatments that inflict additional DNA damage, which is why BRCA-mutated tumors often respond well to platinum-based chemotherapy and to a class of drugs called PARP inhibitors.

PARP Inhibitors and Platinum Sensitivity

PARP inhibitors were the first cancer drugs designed around the concept of synthetic lethality: the idea that losing one DNA repair pathway is survivable for a cell, but losing two simultaneously is fatal. PARP enzymes handle a different type of routine DNA repair. When you block PARP in a cell that has already lost BRCA function, the cell accumulates so much unrepaired damage that it dies.¹⁸ Research suggests the lethal damage involves replication gaps that overwhelm the cell’s remaining protective machinery, though the precise mechanism continues to be refined.¹⁹

Several PARP inhibitors are now approved for ovarian, breast, prostate, and pancreatic cancers in patients with BRCA mutations. Platinum-based chemotherapies work through a related logic: they cause DNA crosslinks that require BRCA-mediated repair to fix. When that repair pathway is broken, the crosslinks persist and kill the cancer cell. BRCA status can therefore shape the entire treatment plan, with mutations that once seemed purely harmful becoming a therapeutic lever.²⁰

However, most patients on PARP inhibitors eventually develop resistance. The most commonly reported mechanism is a reversion mutation: the tumor acquires a second mutation in the same BRCA gene that restores the protein’s function, essentially patching the original flaw. In one remarkable case, sequencing of 11 metastatic sites from a single patient revealed 10 distinct BRCA2 reversion mutations, each independently restoring the gene’s function.²¹ This convergent evolution underscores how strong the selective pressure is: under treatment, any cell that manages to restore DNA repair gains a massive survival advantage.²²

Germline Mutations, Somatic Mutations, and BRCAness

Not all BRCA-mutated cancers arise from inherited mutations. Some tumors acquire BRCA mutations on their own during their development. These somatic mutations are not present in the rest of the body and cannot be passed to children, but within the tumor itself they create the same DNA repair defect. In one national audit of patients with high-grade serous ovarian cancer, about 15% had a detectable BRCA variant. Of those, a little over half were inherited, while the remaining 44% were somatic, found only in the tumor tissue.²³

This matters for treatment because tumors with somatic BRCA mutations respond to PARP inhibitors similarly to those with inherited mutations. A meta-analysis found no significant difference in response rates or progression-free survival between the two groups.²⁴ Clinical data for olaparib, one of the leading PARP inhibitors, showed similar outcomes regardless of whether the BRCA mutation was germline or somatic.²⁵ The practical implication is that tumor testing, not just blood-based genetic testing, can identify patients who might benefit from these therapies.

There is also a third category: tumors where the BRCA genes are structurally intact but silenced through chemical modifications to the DNA. When methyl groups attach to the promoter region of a BRCA gene, the gene gets shut off without being mutated, and the cell behaves as if the gene were broken. This phenomenon, sometimes called BRCAness, means that some patients without any BRCA mutation still have tumors that look and act like BRCA-deficient cancers.²⁶ Sporadic breast and ovarian tumors with BRCA1 promoter silencing share the same biological features as tumors from women who inherited a broken BRCA1 gene.²⁷ Identifying BRCAness is an active area of research because it could expand the pool of patients who benefit from PARP inhibitors and platinum chemotherapy well beyond those with inherited mutations.

Preventive Surgery

For carriers who have not yet developed cancer, preventive surgery remains one of the most effective options. A bilateral risk-reducing mastectomy lowers breast cancer risk by about 90 to 95 percent in BRCA mutation carriers.²⁸ Risk-reducing removal of the fallopian tubes and ovaries (salpingo-oophorectomy) cuts not only the risk of ovarian and tubal cancers but also provides a survival benefit, partly because removing the ovaries lowers circulating estrogen, which in turn reduces breast cancer risk as well. One review noted that risk-reducing salpingo-oophorectomy prevents ovarian-type cancers in about 95% of cases and that the associated reduction in breast and ovarian cancer risks has translated into measurably longer survival.²⁹

The timing of these surgeries involves difficult trade-offs. Removing the ovaries before natural menopause triggers surgical menopause, with consequences for bone health, cardiovascular risk, and quality of life. For breast surgery, the decision is deeply personal and involves weighing a high but not certain cancer risk against permanent physical changes. Enhanced surveillance with breast MRI and mammography is an alternative that catches cancers early without surgery, though it does not prevent them from occurring.

Founder Mutations and Who Should Be Tested

Certain BRCA mutations are far more common in specific populations because of a phenomenon called a founder effect: a mutation that was present in a small ancestral group gets amplified as that group’s descendants grow. The best-known example is in Ashkenazi Jewish populations, where three specific mutations (two in BRCA1 and one in BRCA2) are collectively present in roughly 2% of the population, a rate about ten times higher than the general prevalence of BRCA mutations.³⁰

A complicating factor is that many people do not know their full ancestry. Genetic analysis has found that a sizable fraction of individuals who carry Ashkenazi Jewish founder mutations do not self-report Jewish ancestry, likely because the ancestral connection is several generations back or was never discussed in their family.³¹ Relying solely on self-reported family history to decide who gets tested will miss some high-risk individuals. Founder mutations also exist in other populations, including Icelandic, Norwegian, Dutch, and French Canadian communities, though the specific mutations differ.

Disparities in Testing and Follow-Up

Knowing your BRCA status can be lifesaving, but access to genetic testing and counseling is unevenly distributed. Black women diagnosed with breast cancer are substantially less likely to undergo BRCA testing than white women, even when they have characteristics that suggest a higher probability of carrying a mutation, such as early-onset disease or triple-negative breast cancer. In one population-based study, only about 27% of Black breast cancer survivors had undergone BRCA testing.³² The barriers are multiple: lower awareness of genetic testing, financial obstacles, distrust of the medical system, and fewer referrals from providers.³³

Even among women who do test positive, follow-through on risk-reducing interventions varies by race. Among BRCA carriers in one study, Black women were significantly less likely to undergo preventive mastectomy or salpingo-oophorectomy compared with white and Hispanic women, and discussions about genetic testing with a provider were far less likely to happen in the first place for Black and Spanish-speaking Hispanic women.³⁴ These gaps mean that some of the people who would benefit most from knowing their mutation status are the least likely to find out.

Reproductive Decisions for Carriers

A BRCA diagnosis often arrives during reproductive years, and it intersects with family planning in complicated ways. The recommended timing for preventive ovarian surgery generally falls between the mid-30s and early 40s, which can collide directly with plans to have children. In one survey, 37% of carriers changed their family plans after learning their mutation status, with most choosing to have children sooner or to have fewer children than originally planned.³⁵

Carriers also face the question of whether to use reproductive technologies to avoid passing the mutation to the next generation. Preimplantation genetic testing allows embryos created through IVF to be screened for the family’s specific BRCA mutation before transfer. In the same survey, about 58% of carriers agreed that this kind of testing is justified for BRCA mutations, though only 8% actually went through with it. Fertility preservation through egg or embryo freezing before preventive surgery was discussed by about 28% of carriers with their doctors, and 11% followed through.³⁵ These decisions are deeply individual, shaped by personal values, age, financial resources, and how the carrier feels about the mutation’s implications for future generations.

When Both Copies Are Lost

The cancer risks described above involve carriers who inherited one broken copy of BRCA1 or BRCA2 while retaining one functional copy. In extremely rare cases, a child inherits defective copies from both parents. For BRCA2, biallelic loss causes a subtype of Fanconi anemia, a severe childhood condition characterized by bone marrow failure, developmental abnormalities, and a dramatically elevated risk of childhood cancers including leukemia and solid tumors.³⁶ This discovery linked the BRCA genes to the broader Fanconi anemia DNA-repair network, a connection that deepened scientific understanding of why BRCA loss is so damaging to genomic stability. It also means that when two known BRCA2 carriers have children together, there is a chance of a much more severe outcome than either parent’s cancer predisposition alone.

1
PubMed. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
2
PubMed. Risks of cancer in BRCA1-mutation carriers
3
The Lancet. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
4
PubMed Central. Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution
5
PubMed Central. Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention
6
PubMed. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction
7
PubMed Central. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers
8
Current Problems in Cancer: Case Reports. Management of men with high genetic risk of breast cancer. Is there a place for screening or risk-reducing surgery? Case report and review.
9
PubMed Central. Male BRCA mutation carriers: clinical characteristics and cancer spectrum
10
British Journal of Cancer. BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis
11
PubMed Central. BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update.
12
British Journal of Cancer. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
13
BJC Reports. A prospective observational study of pancreatic cancer risk in men and women with pathogenic variants in BRCA1 or BRCA2
14
PubMed Central. The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation
15
PubMed Central. Skin cancer risk in BRCA1/2 mutation carriers
16
PubMed. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
17
PubMed Central. Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer
18
PubMed Central. PARP inhibitors: Synthetic lethality in the clinic.
19
Molecular Cell. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
20
PubMed Central. Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
21
npj precision oncology. Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
22
PubMed Central. BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges
23
PubMed Central. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high‐grade serous ovarian cancer: a national retrospective audit
24
PubMed Central. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
25
PubMed Central. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
26
PubMed Central. BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine
27
PubMed Central. Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy
28
PubMed. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review
29
PubMed Central. Prophylactic Surgery: For Whom, When and How?
30
PubMed Central. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families
31
Scientific Reports. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry
32
PubMed Central. Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study
33
PubMed. Racial/Ethnic Disparities in BRCA Counseling and Testing: a Narrative Review
34
PubMed Central. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors
35
PubMed Central. Attitude of BRCA1/2 mutation carriers towards fertility preservation, family planning and preimplantation genetic testing for primary prevention of breast and ovarian cancer in the next generation
36
PubMed. Biallelic inactivation of BRCA2 in Fanconi anemia